Anticancer Activity and Protein Phosphatase 1 and 2A Inhibition of a New Generation of Cantharidin Analogues Jennette A. SakoffStephen P. AcklandAdam McCluskey OriginalPaper Pages: 1 - 11
Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice Lisa PolinKathryn WhiteThomas H. Corbett OriginalPaper Pages: 13 - 22
Lack of in Vitro – in Vivo Correlation of a Novel Investigational Anticancer Agent, SH 30 Srinivasu PoondruRalph E. ParchmentBhaskara R. Jasti OriginalPaper Pages: 23 - 33
Partial Circumvention of P-Glycoprotein-Mediated Multidrug Resistance by Doxorubicin-14-O-Hemiadipate Olga V. LeontievaMaria N. PreobrazhenskayaRalph J. Bernacki OriginalPaper Pages: 35 - 48
Chemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome – Recall Following Different Chemotherapy Agents Yuk Fung HuiFrancis J. GilesJorge E. Cortes OriginalPaper Pages: 49 - 53
Phase I Study of JM-216 (an Oral Platinum Analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies Suzanne JonesJohn HainsworthF. Anthony Greco OriginalPaper Pages: 55 - 61
Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU) Patricia M. LoRussoSucharu PrakashBhaskara Jasti OriginalPaper Pages: 63 - 71
Phase I/II Study of Gemcitabine plus Vinorelbine in Non-Small Cell Lung Cancer Emilio EstebanJoaquin FraAngel Jimenez Lacave OriginalPaper Pages: 73 - 82
Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies J.H.M. SchellensB. HeinrichA.R. Hanauske OriginalPaper Pages: 83 - 93
Phase II Trial of Docetaxel Chemotherapy in Patients with Incurable Adenocarcinoma of the Esophagus Elisabeth I. HeathSusan UrbaArlene A. Forastiere OriginalPaper Pages: 95 - 99
Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Renal Cell Cancer Keith M. Skubitz OriginalPaper Pages: 101 - 104
A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study Robert P. WhiteheadJoseph M. UngerVernon K. Sondak OriginalPaper Pages: 105 - 111
Phase II Trial of Amonafide in Central Nervous System Tumors: A Southwest Oncology Group Study Sarah A. TaylorCathryn RankinKurt Jaeckle OriginalPaper Pages: 113 - 115
The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study James K. WeickJohn J. CrowleyBart Barlogie OriginalPaper Pages: 117 - 121
A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck David G. PfisterJohn McCaffreyIlana Palgi OriginalPaper Pages: 123 - 127
Phase II Trial of Topotecan by Continuous Infusion in Patients with Advanced Soft Tissue Sarcomas, a SWOG Study G. Thomas BuddCathryn RankinKaren Antman OriginalPaper Pages: 129 - 132
Raltitrexed (Tomudex) Administration in Patients Failing Multiple Prior Chemotherapy Regimens in Advanced Colorectal Cancer: a Pilot Study N. TsavarisC. KosmasCh. Koufos OriginalPaper Pages: 133 - 136